Cost Effectiveness of Tofacitinib for the Treatment of Active Ankylosing Spondylitis in Greece

ConclusionsTofacitinib was estimated to be a cost-effective option for the treatment of active ankylosing spondylitis in Greece for both biologic-naive and biologic-experienced patients.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research